Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | ACACB | O00763 | 4/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 2/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5548799 | 1.00 | DRD2 (0.55) | DRD2ACACBSIGMAR1KDM4DKDM1A | |
| SCHEMBL5548788 | 0.84 | DRD2 (0.47) | DRD2ACACBKDM4DAAK1 | |
| SCHEMBL5543202 | 0.84 | DRD2 (0.54) | DRD2ACACBSIGMAR1KDM1AMAOB | |
| SCHEMBL5548352 | 0.84 | DRD2 (0.54) | DRD2ACACBSIGMAR1KDM1AMAOB | |
| SCHEMBL5549964 | 0.84 | DRD2 (0.54) | DRD2ACACBSIGMAR1KDM1AMAOB | |
| SCHEMBL5548746 | 0.80 | DRD2 (0.49) | DRD2KDM4DAAK1 | |
| SCHEMBL5545235 | 0.80 | DRD2 (0.49) | DRD2KDM4DAAK1 | |
| SCHEMBL5548342 | 0.80 | DRD2 (0.49) | DRD2KDM4DAAK1 | |
| SCHEMBL2649560 | 0.80 | KDM1A (0.55) | DRD2ACACBKDM1AMAOBKCNA3 | |
| SCHEMBL2649557 | 0.80 | KDM1A (0.55) | DRD2ACACBKDM1AMAOBKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | claimed |
| US-7230002-B2 | Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-06-12 | — | — | US | disclosed |
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | DPP4, DPP3, DPP7 | DRD2 3398/4885ACACB 1421/4885SIGMAR1 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.